This issue covers the period 19 August – 2 September 2026. Our editors have selected eight items with the broadest regulatory-affairs impact for multi-market device manufacturers and consultancies. Headlines this fortnight: the MHRA tables sweeping legislative reform amendments in the UK Health Bill; a formal device safety investigation flags elevated revision-surgery risk for cobalt-chrome modular neck hips; a cyberattack wave hitting major medtech OEMs raises supply-chain and cybersecurity-plan obligations for the whole sector; and Health Canada quietly revamps its Special Access Programme application process. Read on for the full picture.
MHRA Regulatory Reform Amendments Tabled in UK Health Bill
MHRA · UK
These proposed amendments would reshape the UK's medical device licensing regime — including information-sharing powers and the architecture of a future product-authorisation framework. For any manufacturer maintaining or planning UKCA routes, this is the earliest legislative signal of how post-Brexit UK regulation will diverge from (or align with) EU MDR. Regulatory-affairs teams should monitor parliamentary progress closely and consider submitting stakeholder views before the Bill advances.
Read the source →MHRA DSI/2026/010 — Cobalt-Chrome Modular Neck Hip Replacements: Elevated Risk of Wear, Corrosion & Revision Surgery
MHRA · UK
A formal MHRA Device Safety Investigation covering multiple Co-Cr modular neck hip stems has found increased wear and corrosion leading to adverse local tissue reactions and a potential rise in revision-surgery rates. Manufacturers of implantable orthopaedic components, their post-market surveillance teams, and distributors must review whether their devices are in scope, assess PMCF data, and consider whether field safety corrective actions or enhanced patient follow-up communications are required under both UK and EU MDR obligations.
Read the source →NGPod pH Testing Device (DSI/2026/009) — Quarantine and Dispose of All UK Stock Immediately
MHRA · UK
The NGPod handheld pH device (used to confirm nasogastric tube placement) has been withdrawn from the UK market after the manufacturer ceased trading. MHRA requires users to quarantine and dispose of all remaining units. This is a direct action item for NHS procurement, distributors, and any consultancy advising on post-market surveillance or economic operator obligations — and a reminder that manufacturer insolvency triggers specific competent-authority notification duties under UK MDR.
Read the source →FDA Recognised Consensus Standards Updated — Recognition List Number 066
FDA · US
FDA has published modifications to its list of recognised consensus standards (Recognition List 066). Manufacturers who declare conformity with consensus standards as part of 510(k), De Novo, or PMA submissions must verify their chosen standards remain on the current list — and update declarations of conformity where standards have been added, revised, or withdrawn. This is a routine but operationally important check for any device programme in active premarket review.
Read the source →Health Canada Revamps Special Access Programme (SAP) Application Process for Medical Devices
Health Canada · CA
Health Canada has issued a notice detailing new changes to the SAP application process for medical devices. Manufacturers and distributors supplying devices to Canadian customers under SAP authorisations — common for devices not yet licensed in Canada or for compassionate-use scenarios — must update internal SOPs and submission templates to reflect the revised requirements. Failure to align could result in delays or rejections for time-sensitive patient access requests.
Read the source →Cyberattack Wave Hits Medtech Sector — Boston Scientific Operations Disrupted Globally
INDUSTRY · GLOBAL
Boston Scientific disclosed that a cyberattack disrupted global ordering and shipping operations, with full scope still being assessed. This follows similar incidents at Stryker, Medtronic, and Abbott in 2026. For regulatory-affairs and quality teams, this is a direct prompt to review cybersecurity incident-response plans, assess supply-chain continuity obligations under EU MDR/IVDR Article 10 and FDA guidance, and confirm that any networked or software-enabled devices have up-to-date cybersecurity documentation for regulators.
Read the source →FDA Seeks Feedback on Generative AI Regulation for Medical Devices
INDUSTRY · GLOBAL
FDA published a discussion paper exploring the 'unique risks' and potential of generative AI in patient care, inviting stakeholder input. For manufacturers developing or integrating AI/ML-enabled devices, this represents a critical pre-rulemaking window to shape how generative AI will be classified, validated, and overseen. Regulatory teams should evaluate current AI/ML submissions against emerging expectations and consider submitting formal comments to influence the framework.
Read the source →MHRA Safety Roundup: August 2026 — Summary of All Device and Medicine Alerts
MHRA · UK
The August 2026 MHRA Safety Roundup consolidates all device and medicine safety communications issued during the month, including Field Safety Notices for 17–21 August. Regulatory teams responsible for UK vigilance and post-market surveillance should review the full roundup to confirm no in-scope devices or components are affected, and to cross-reference against their own periodic safety update reports and FSCA obligations.
Read the source →